Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Clinical and Legal Considerations in Pharmaceutical Compounding JCAD The Journal of Clinical and Aesthetic Dermatology Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 ( compounding only, no legal prescribing) into Category 1. This means